Skip to main content
. 2016 Oct 25;12:2707–2714. doi: 10.2147/NDT.S114955

Table 4.

Meta-analysis for the safety outcomes (continuous data)

Outcome Studies (n) Participants analyzed (n)
WMD (95% CI) I2 (%) P-value
Levomilnacipran Placebo
Pulse rate 4 1,298 756 7.56 (6.81, 8.31) 20 <0.00001
SBP 4 1,300 756 3.14 (2.37, 3.90) 0 <0.00001
DPB 4 1,300 756 3.45 (2.86, 4.05) 0 <0.00001
QTcB 3 1,171 631 8.59 (6.97, 10.20) 0 <0.00001

Abbreviations: WMD, weighted mean difference; CI, confidence interval; SBP, systolic blood pressure; DPB, diastolic blood pressure.